Occupationally acquired HIV infections in health care workers (HCW) in Germany;Berufsbedingte HIV-infektionen bei medizinischem personal

Arbeitsmedizin Sozialmedizin Umweltmedizin

Volumn 37, Issue 5, 2002, Pages 218-231

  Jarke, J ^a   Marcus, U ^a  

^a ROBERT KOCH INSTITUTE   (Germany)

Author keywords

Compensation for occupationally acquired HIV AIDS; HIV post exposure prophylaxis (PEP); Occupational HIV infection

Indexed keywords

EFAVIRENZ; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; RITONAVIR; ZIDOVUDINE;

CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE TRANSMISSION; GERMANY; HEALTH CARE PERSONNEL; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; OCCUPATIONAL ACCIDENT; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HAZARD; REVIEW; RISK FACTOR; WORKPLACE;

EID: 0036244972     PISSN: 09446052     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. Occupational infection with human immunodeficiency virus (HIV)
2. Occupational risk of human immunodeficiency virus infection in healthcare workers: An overview
3. HIV transmission after an occupational exposure despite postexposure prophylaxis with a combination drug regimen
4. A case-control study of HIV seroconversion in health care workers after percutaneous exposure to HIV-infected blood: Clinical and public health implications
5. Update: Universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other bloodborne pathogens in health-care settings
6. Guidelines for prevention of transmission of human immunodeficiency virus and hepatitis B virus to health-care and public-safety workers
7. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV and HIV and recommendations for postexposure prophylaxis
8. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures-worldwide, 1997-2000
9. Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood-France, United Kingdom and United States, January 1988-August 1994
10. Surveillance for occupationally acquired HIV infection - United States, 1981-1992
11. Duration of time between exposure and seroconversion in healthcare workers with occupationally acquired infection with human immunodeficiency virus
12. Reduction of maternal-infant transmission of human immunodeficiency virus type I with zidovudine treatment
13. Postexpositionelle prophylaxe nach HIV-Exposition - Deutsch-österreichische empfehlungen
14. HIV-I infection transmitted by serum droplets into the eye: A case report
15. Frequency of nonparenteral occupational exposures to blood and body fluids before and after universal precautions training
16. Postexposure chemoprophylaxis with ZDV or ZDV combined with interferon-a: Failure after inoculating rhesus monkeys with a high dose of SIV
17. Management of occupational exposures to blood-borne viruses
18. Prophylaxis for occupational exposure to HIV
19. Management of occupational exposures to bloodborne pathogens: Hepatitis B virus, hepatitis C virus, and human immunodeficiency virus
20. Incidence and prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and cytomegalovirus among health care personnel at risk for blood exposure: Final report from a longitudinal study
21. Is antiretroviral treatment after percutaneous HIV exposure justified?
22. HIV Transmission by needle stick and exzematous lesion: Three cases from Germany
23. Berufsbedingte HIV-Infektion bei einer krankenschwester und ihrern kind
24. Berufsbedingte HIV-Infektion durch blutspritzer ins auge
25. Risk for occupational transmission of human immunodeficiency virus type 1 (HIV-I) associated with clinical exposures: A prospective evaluation
26. Risk for occupational transmission of human immunodeficiency virus type 1 (HIV-I) associated with clinical exposures. A prospective evaluation
27. Prophylactic zidovudine after occupational exposure to the human immunodeficiency virus: An interim analysis
28. Long-term follow-up of health care workers with work-site exposure to human immunodeficiency virus
29. Postinoculation PMPA treatment, but not preinoculation immunomodulatory therapy, protects against development of acute disease induced by the unique simian immunodeficiency virus SIVsmmPBj
30. HIV-Infektion und AIDS als berufskrankheit
31. Berufsbedingte HIV-Infektionen bei medizinischem personal - 19 Fallgeschichten aus deutschland
32. Berufskrankheit HIV/AIDS aus juristischer und medizinisch-gutachterlicher sicht
33. AIDS am arbeitsplatz: HIV-infizierte beschäftigte im gesundheitswesen
34. Failures of zidovudine postexposure prophylaxis
35. Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers
36. HIV transmission by stabbing despite zidovudine prophylaxis
37. A double-blind, placebo-controlled study of the safety and efficacy of retrovir® (zidovudine, ZDV) as a chemoprophylactic agent in health care workers exposed to HIV
38. Failure of zidovudine prophylaxis after accidental exposure to HIV-I
39. Containment of simian immunodeficiency virus infection: Cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment
40. Failed prophylactic zidovudine after needlestick injury
41. Effects of initiation of 3′-azido, 3′-deoxythymidine (zidovudine) treatment at different times after infection of rhesus monkeys with simian immunodeficiency virus
42. Efficacy of gloves in reducing blood volumes transferred during simulated needlestick injury
43. Can HIV-I infection be transmitted by a "discarded" syringe?
44. Suppression of acute viremia by short-term postexposure prophylaxis of simian/human immunodeficiency virus SHIV-RT-infected monkeys with a novel reverse transcriptase inhibitor (GW420867) allows for development of potent antiviral immune responses resulting in efficient containment of infection
45. Der betriebsarzt im spannungsfeld zwischen schweigepflicht und meldepflicht
46. Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2)
47. Tolerability and side-effects of post-exposure prophylaxis for HIV infection
48. HIV-I transmission by a needlestick injury despite rapid initiation of four-drug postexposure prophylaxis
49. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV
50. Immune response to human immunodeficiency virus (HIV) in healthcare workers occupationally exposed to HIV-contaminated blood
51. Zidovudine in post-exposure prophylaxis of health-care workers
52. Occupational HIV transmission by an internal fixation wire of the patella
53. Misdiagnosis of HIV infection by HIV-I plasma viral load testing: A case series
54. HIV infection and needle-stick injuries with syringes discarded by drug abusers
55. Überlegungen zur medikamentösen postexpositionsprophylaxe nach beruflicher HIV-Exposition
56. Zur problematik der nosokomialen übertragung von HIV
57. Berufsbedingte HIV-Infektionen bei medizinischem personal
58. Fallbericht: Beruflich erworbene HIV-infektion nach kanülenstichverletzung
59. Antiretroviral therapy during primary immunodeficiency virus infection can induce persistent suppression of virus load and protection from heterologous challenge in rhesus macaques
60. Occupational HIV-infection documented by sequence analysis of source and index virus strains
61. HIV-Infektion durch nadelstichverletzung
62. Genotypic analysis of HIV-I isolates to identify antiretroviral resistance mutations from source patients involved in health care worker occupational exposures
63. Percutaneous injuries during surgical procedures
64. A survey of occupational blood contact and HIV infection among orthopedic surgeons
65. Surveillance of HIV infection and zidovudine use among health care workers after occupational exposure to HIV-infected blood
66. mne infection depends critically on timing of initiation and duration of treatment
67. Effect of dosing frequency on ZDV prophylaxis in macaques infected with simian immunodeficiency virus
68. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl) adenine
69. Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: Oral 3-azido-3-deoxythymidine prevents SIV infection
70. Early short-term 9-[2-(R)-(Phosphonomethoxy)Propyl]Adenine treatment favourably alters the subsequent disease course in simian immunodeficiency virus-infected newborn rhesus macaques
71. Prophylactic and therapeutic benefits of short-term 9-[2-(R)-(Phosphonomethoxy)Propyl]Adenine (PMPA) administration to newborn macaques following oral inoculation with simian immunodeficiency virus with reduced susceptibility to PMPA
72. Experience of healthcare workers taking postexposure prophylaxis after occupational HIV exposures: Findings of the HIV postexposure prophylaxis registry